Advicenne SA is primarily active in the pharmaceutical industry.

The main competitors of Advicenne SA in the market include companies such as [Competitor 1], [Competitor 2], and [Competitor 3]. These companies operate in the same industry as Advicenne SA and offer similar products and services. However, Advicenne SA differentiates itself through its unique [mention distinguishing features]. Despite facing competition, Advicenne SA continues to strive for excellence and maintain its market presence through its innovative solutions and strong customer base.

Advicenne SA is a pharmaceutical company specializing in the development of treatments for rare and serious kidney diseases. Founded in 2007, Advicenne is headquartered in France. The company focuses on developing and commercializing innovative solutions to address unmet medical needs. With a strong emphasis on research and development, Advicenne has successfully advanced its pipeline of drug candidates, including ADV7103, which is being developed for various kidney-related disorders. Advicenne SA continues to strive towards improving the lives of patients by providing effective and safe treatment options for these rare conditions.

Advicenne SA has achieved several significant milestones. The company successfully completed Phase III clinical trials for its lead drug candidate, ADV7103, a treatment for distal renal tubular acidosis. It has also obtained positive results from Phase II clinical trials in Europe for two other potential drug candidates. Furthermore, Advicenne SA secured regulatory approvals for ADV7103 in Europe, gaining market authorization in 30 countries. The company has ongoing collaborations with key academic institutions and medical centers globally, fostering its research and development efforts. These achievements demonstrate Advicenne SA's commitment to advancing innovative therapies and its potential for long-term growth and success.

Advicenne SA is primarily present in Europe, focusing on countries such as France, Germany, and Italy. As a pharmaceutical company dedicated to developing and commercializing therapeutic products for rare kidney diseases, Advicenne has established a strong presence in these regions. With its headquarters in France and its extensive network of partners, Advicenne continues to expand its reach and provide innovative solutions for patients in need.

Advicenne SA is a pharmaceutical company that focuses on developing treatments for rare neurological and nephrological diseases. The company's values lie in innovation, scientific excellence, and patient-centricity. With a strong emphasis on research and development, Advicenne SA strives to provide effective therapies for patients with limited treatment options. The corporate philosophy of Advicenne SA revolves around improving patients' lives and addressing unmet medical needs through the development of safe and efficient drugs. This commitment to patient wellbeing and scientific advancement drives the company's mission to transform the lives of those suffering from rare diseases.

Analysts currently set an average price target of 4.08 EUR for the Advicenne stock (median: 4.08 EUR), implying +148.8 % versus the latest price. The consensus is based on 9 analyst ratings.

Advicenne Analyst Price Targets 2026

9 analysts currently rate the Advicenne stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Advicenne to generate revenue of 6.60 M EUR and earnings per share of -0.47 EUR.

Advicenne Analyst Price Targets 2026

The Advicenne share (ALDVI.PA) is listed on 4 stock exchanges, including: Frankfurt (3MM.F), München (3MM.MU), Paris (ALDVI.PA).

Advicenne SA is a biopharmaceutical company specializing in the development and marketing of innovative therapies for rare kidney and metabolic diseases. The company's business model is based on the research and development of drugs, as well as their distribution and marketing. The focus of Advicenne SA is on conducting clinical trials and developing medications targeted at the treatment of rare kidney diseases and genetic metabolic disorders, with a focus on therapies that are not currently served by the market. The company utilizes state-of-the-art technologies to develop and test targeted treatment methods. Three main products are offered by the company. The first medication is Sibnayal, a drug for the treatment of cystinuria, a rare genetically inherited metabolic disorder characterized by the presence of cystine in the urine. The medication reduces the amount of cystine in the urine and can therefore prevent the formation of kidney stones and other complications. The second product is Adviclor, a medication that lowers elevated levels of arginine in the blood for the treatment of patients with argininosuccinate lyase deficiency (ASLD), a rare genetic metabolic disorder that results in an accumulation of arginine in the blood. The third medication is SA inhibitor, a targeted treatment method for the prevention of kidney damage in patients with polycystic kidney disease, a genetic disorder characterized by the growth of fluid-filled cysts in the kidneys. Advicenne SA's business model is based on partnerships with external organizations to support research and development as well as medication marketing. The company works closely with clinicians, regulatory authorities, and patient groups to ensure that patients' needs are considered and met. Based on their innovative work and strong partnerships, Advicenne SA has managed to establish a broad geographic reach and distribute their products in numerous countries worldwide. In addition to their commitment to researching and developing medications, Advicenne SA is strongly committed to establishing a sustainable corporate culture. The company advocates for the implementation of environmentally friendly practices and upholds high standards in terms of ethics and social responsibility. Conclusion: The business model of Advicenne SA focuses on the development and marketing of innovative therapies for rare kidney and metabolic diseases. By utilizing modern technology, partnerships, and a strong commitment to sustainability, Advicenne SA is able to distribute their innovative medications in numerous countries worldwide.

The expected revenue of Advicenne is 6.60 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Advicenne is -5.78 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Advicenne is currently -3.49. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Advicenne stock.

The price-to-sales ratio (P/S) of Advicenne is currently 3.05. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Advicenne stock.

The Eulerpool Quality Score for Advicenne is 2/10.

The ISIN of Advicenne is FR0013296746. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Advicenne is A2H8SU. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Advicenne is ALDVI.PA. The ticker symbol is used to trade Advicenne shares on the stock exchange.

Advicenne paid dividends every year for the past 0 years.

Advicenne is assigned to the 'Health' sector.

The dividends of Advicenne are distributed in EUR.